Karin Bystol

Statistics

Publications

Citations

134

H-Index

Active since

2016

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

WuXi AppTec (China)

Karin Bystol is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, antiviral resistance, and antiviral agents.

Publications per year

2016–2018

Publications

The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons

Frederick Lahser, Karin Bystol, Stephanie Curry et al. · Antimicrobial Agents and Chemotherapy · 2016 · 58 citations · Full text

Medicine, Infectious Diseases, Pharmacology +17

Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms

Ling Tong, Wensheng Yu, Lei Chen et al. · Journal of Medicinal Chemistry · 2016 · 47 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

Structure–activity relationships of proline modifications around the tetracyclic-indole class of NS5A inhibitors

Ling Tong, Wensheng Yu, Craig A. Coburn et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 16 citations

Pharmacy, Medicinal Chemistry, Pharmacology +16

Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions

Wensheng Yu, Ling Tong, Oleg Selyutin et al. · Journal of Medicinal Chemistry · 2018 · 13 citations

Medicine, Medicinal Chemistry, Pharmacology +17

1–4 of 4